20°C / 22°C
  • Sat
  • 21°C
  • 10°C
  • Sun
  • 22°C
  • 9°C
  • Mon
  • 22°C
  • 9°C
  • Tue
  • 24°C
  • 10°C
  • Wed
  • 23°C
  • 11°C
  • Thu
  • 23°C
  • 9°C
  • Sat
  • 19°C
  • 10°C
  • Sun
  • 19°C
  • 11°C
  • Mon
  • 19°C
  • 14°C
  • Tue
  • 18°C
  • 11°C
  • Wed
  • 15°C
  • 11°C
  • Thu
  • 18°C
  • 11°C
  • Sat
  • 22°C
  • 12°C
  • Sun
  • 25°C
  • 11°C
  • Mon
  • 25°C
  • 12°C
  • Tue
  • 26°C
  • 12°C
  • Wed
  • 26°C
  • 12°C
  • Thu
  • 26°C
  • 11°C
  • Sat
  • 22°C
  • 10°C
  • Sun
  • 23°C
  • 8°C
  • Mon
  • 23°C
  • 10°C
  • Tue
  • 25°C
  • 9°C
  • Wed
  • 26°C
  • 7°C
  • Thu
  • 23°C
  • 6°C
  • Sat
  • 24°C
  • 19°C
  • Sun
  • 25°C
  • 18°C
  • Mon
  • 26°C
  • 18°C
  • Tue
  • 26°C
  • 18°C
  • Wed
  • 28°C
  • 19°C
  • Thu
  • 24°C
  • 19°C
  • Sat
  • 20°C
  • 12°C
  • Sun
  • 20°C
  • 14°C
  • Mon
  • 22°C
  • 13°C
  • Tue
  • 19°C
  • 15°C
  • Wed
  • 20°C
  • 13°C
  • Thu
  • 18°C
  • 12°C
  • Sat
  • 24°C
  • 11°C
  • Sun
  • 23°C
  • 12°C
  • Mon
  • 21°C
  • 13°C
  • Tue
  • 18°C
  • 10°C
  • Wed
  • 16°C
  • 9°C
  • Thu
  • 16°C
  • 9°C
  • Sat
  • 19°C
  • 12°C
  • Sun
  • 21°C
  • 12°C
  • Mon
  • 21°C
  • 14°C
  • Tue
  • 17°C
  • 12°C
  • Wed
  • 16°C
  • 11°C
  • Thu
  • 17°C
  • 11°C
  • Sat
  • 24°C
  • 12°C
  • Sun
  • 26°C
  • 11°C
  • Mon
  • 26°C
  • 12°C
  • Tue
  • 27°C
  • 10°C
  • Wed
  • 27°C
  • 10°C
  • Thu
  • 27°C
  • 13°C
  • Sat
  • 21°C
  • 8°C
  • Sun
  • 23°C
  • 8°C
  • Mon
  • 23°C
  • 10°C
  • Tue
  • 24°C
  • 9°C
  • Wed
  • 25°C
  • 10°C
  • Thu
  • 16°C
  • 4°C
  • Sat
  • 21°C
  • 14°C
  • Sun
  • 24°C
  • 13°C
  • Mon
  • 24°C
  • 12°C
  • Tue
  • 28°C
  • 10°C
  • Wed
  • 26°C
  • 13°C
  • Thu
  • 29°C
  • 11°C
  • Sat
  • 22°C
  • 11°C
  • Sun
  • 20°C
  • 13°C
  • Mon
  • 24°C
  • 14°C
  • Tue
  • 18°C
  • 13°C
  • Wed
  • 21°C
  • 12°C
  • Thu
  • 17°C
  • 11°C

Pfizer ends research for new Alzheimer's, Parkinson's drugs

Pfizer has invested heavily in research for Parkinson’s and Alzheimer‘s, and is one of several drugmakers, along with GlaxoSmithKline and Eli Lilly, that is part of the Dementia Discovery Fund.

Pfizer's corporate headquarters stand in midtown Manhattan on a morning where volunteers with Doctors Without Borders dumped $17 million in fake money outside of the building to protest high vaccine prices on November 12, 2015 in New York City. Picture: AFP

NEW YORK - Pfizer Inc is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease, the US pharmaceutical company announced on Saturday.

The company said it expects to eliminate 300 positions from the neuroscience discovery and early development programs in Andover and Cambridge, Massachusetts, and Groton, Connecticut, as it redistributes the money spent on research, according to the emailed statement.

Pfizer is not making any changes to research and development funding for tanezumab, which is marketed as a treatment for joint pain from osteoarthritis, fibromyalgia treatment Lyrica, or its rare disease program.

“This was an exercise to re-allocate spend across our portfolio, to focus on those areas where our pipeline, and our scientific expertise, is strongest,” the company said.

Pfizer has invested heavily in research for Parkinson’s and Alzheimer‘s, and is one of several drugmakers, along with GlaxoSmithKline and Eli Lilly, that is part of the Dementia Discovery Fund, a venture capital fund launched in 2015 by industry and government groups that seeks to develop treatments for Alzheimer‘s.

However, some of Pfizer’s investments have resulted in disappointment.

In 2012, Pfizer and partner Johnson & Johnson called off additional work on the drug bapineuzumab after it failed to help patients with mild to moderate Alzheimer’s in its second round of clinical trials.

The company said on Saturday that it will launch a new venture fund to invest in neuroscience research projects.
Pfizer is expected to make a presentation on Monday at the JP Morgan healthcare conference in San Francisco, a key annual event for healthcare investors.

Comments

EWN welcomes all comments that are constructive, contribute to discussions in a meaningful manner and take stories forward.

However, we will NOT condone the following:

- Racism (including offensive comments based on ethnicity and nationality)
- Sexism
- Homophobia
- Religious intolerance
- Cyber bullying
- Hate speech
- Derogatory language
- Comments inciting violence.

We ask that your comments remain relevant to the articles they appear on and do not include general banter or conversation as this dilutes the effectiveness of the comments section.

We strive to make the EWN community a safe and welcoming space for all.

EWN reserves the right to: 1) remove any comments that do not follow the above guidelines; and, 2) ban users who repeatedly infringe the rules.

Should you find any comments upsetting or offensive you can also flag them and we will assess it against our guidelines.

EWN is constantly reviewing its comments policy in order to create an environment conducive to constructive conversations.

comments powered by Disqus